These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3622862)

  • 21. Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy.
    Nishino T; Toki F; Oyama H; Shimizu K; Shiratori K
    Intern Med; 2006; 45(8):497-501. PubMed ID: 16702740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of intravenous and oral prednisolone.
    Al-Habet S; Rogers HJ
    Br J Clin Pharmacol; 1980 Nov; 10(5):503-8. PubMed ID: 7437263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mizoribine for the treatment of lupus nephritis in children and adolescents.
    Tanaka H; Tsugawa K; Tsuruga K; Suzuki K; Nakahata T; Ito E; Waga S
    Clin Nephrol; 2004 Dec; 62(6):412-7. PubMed ID: 15630899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome.
    Eguchi A; Takei T; Yoshida T; Tsuchiya K; Nitta K
    Nephrol Dial Transplant; 2010 Jan; 25(1):124-9. PubMed ID: 19740915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
    Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
    Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Improvement of the maintenance therapy after methylprednisolone pulse therapy--effect of prednisolone combined with immunosuppressants].
    Miyamae T; Nakasima S; Imagawa T; Ito S; Katakura S; Tomono N; Mori M; Ibe M; Mitsuda T; Aihara Y; Yokota S
    Ryumachi; 1999 Dec; 39(6):829-35. PubMed ID: 10695406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan.
    Imai T; Utsugisawa K; Murai H; Tsuda E; Nagane Y; Suzuki Y; Minami N; Uzawa A; Kawaguchi N; Masuda M; Konno S; Suzuki H; Akaishi T; Aoki M
    J Neurol Neurosurg Psychiatry; 2018 May; 89(5):513-517. PubMed ID: 29175893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioavailability and reversible metabolism of prednisone and prednisolone in man.
    Garg V; Jusko WJ
    Biopharm Drug Dispos; 1994 Mar; 15(2):163-72. PubMed ID: 8011967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies comparing the metabolic clearance rate of 11 beta,17,21-trihydroxypregn-1,4-diene-3,20-dione (prednisolone) after oral 17,21-dihydroxypregn-1,4-diene-3,11,20-trione and intravenous prednisolone.
    Hsueh WA; Paz-Guevara A; Bledsoe T
    J Clin Endocrinol Metab; 1979 May; 48(5):748-52. PubMed ID: 429520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children.
    Hiraoka M; Tsukahara H; Matsubara K; Tsurusawa M; Takeda N; Haruki S; Hayashi S; Ohta K; Momoi T; Ohshima Y; Suganuma N; Mayumi M;
    Am J Kidney Dis; 2003 Jun; 41(6):1155-62. PubMed ID: 12776266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of prednisolone after high doses of prednisolone hemisuccinate.
    Derendorf H; Rohdewald P; Möllmann H; Rehder J; Barth J; Neveling D
    Biopharm Drug Dispos; 1985; 6(4):423-32. PubMed ID: 4084667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Glucocorticoid therapy in renal diseases--its indication and therapeutic schedule].
    Koide K; Sano M
    Nihon Rinsho; 1994 Mar; 52(3):728-33. PubMed ID: 8164374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of single-dose oral mizoribine pulse therapy twice per week for frequently relapsing steroid-dependent nephrotic syndrome.
    Fujieda M; Ishihara M; Morita T; Hayashi A; Okada S; Ohta T; Sakano T; Wakiguchi H
    Clin Nephrol; 2012 Jul; 78(1):40-6. PubMed ID: 22732336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of mizoribine and prednisolone combination therapy in adult patients with IgA vasculitis.
    Mima A
    Rheumatol Int; 2017 Aug; 37(8):1387-1393. PubMed ID: 28255645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prednisone and prednisolone bioavailability in renal transplant patients.
    Gambertoglio JG; Frey FJ; Holford NH; Birnbaum JL; Lizak PS; Vincenti F; Feduska NJ; Salvatierra O; Amend WJ
    Kidney Int; 1982 Apr; 21(4):621-6. PubMed ID: 7047863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypogammaglobulinemia in steroid-dependent asthmatics correlates with the daily dose of oral prednisolone.
    Kawano T; Matsuse H; Obase Y; Kondo Y; Machida I; Tomari S; Mitsuta K; Fukushima C; Shimoda T; Kohno S
    Int Arch Allergy Immunol; 2002 Jul; 128(3):240-3. PubMed ID: 12119507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic treatment with prednisolone represses the circadian oscillation of clock gene expression in mouse peripheral tissues.
    Koyanagi S; Okazawa S; Kuramoto Y; Ushijima K; Shimeno H; Soeda S; Okamura H; Ohdo S
    Mol Endocrinol; 2006 Mar; 20(3):573-83. PubMed ID: 16269518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
    Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.